Pharmaceutical Product Development (PPDI) Reports Inline Q3 EPS of $0.32
More News related to PPDI
- PPD, Inc. (PPDI) Agrees to Acquire BioDuro
- PPD to Acquire BioDuro
- PPD, Inc. (PPDI) Announces Agreement with Janssen Pharmaceutica to Commercialize 2 Phase II-Ready Therapeutic Compounds
- PPD and Janssen Pharmaceutica Collaborate to Develop Compounds for Treatment of Irritable Bowel Syndrome and Bacterial Infections
- PPD (PPDI) Declares $0.15 Quarterly Dividend; 2.9% Yield
More News related to Earnings
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Pharmaceutical Product Development (NASDAQ: PPDI) reports Q3 EPS of $0.32, inline with the analyst estimate of $0.32. Revenue for the quarter was $341.1 million, which compares to the estimate of $334.16 million.
Related Categories
EarningsStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
